N/A N=50 The Right Ventricular Pulmonary Circulation Continuum in Mitral Valve Disease Study
Mitral Regurgitation · Pulmonary Hypertension
Primary: Impaired Post-operative Functional Capacity — 35 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=128 Ertugliflozin for Functional Mitral Regurgitation
Mitral Valve Insufficiency · Left Ventricular Systolic Dysfunction
Primary: Change of EROA — 0.03; -0.05 square cm — p=<0.001
N/A N=111 Left Atrial Distensibility to Predict Left Ventricular Filling Pressure and Prognosis in Patients With Severe Mitral Regurgitation
Mitral Valve Insufficiency · Atrial Fibrillation · Heart Failure
Primary: Left Ventricular Filling Pressure More Than 15 mmHg Measured by Left Ventricular Catheterization — 25.5 mmHg
Phase 2 N=55 Feasibility Study of a Percutaneous Mitral Valve Repair System.
Mitral Valve Insufficiency · Mitral Valve Regurgitation · Mitral Valve Incompetence
Primary: Mitral Regurgitation Severity — 0.0; 0.0; 5.6; 38.9 Percentage of participants
N/A N=208 Minimally Invasive or Conventional Edge-To-Edge Repair for Severe Mitral Regurgitation Due to Bileaflet Prolapse in Barlow's Disease: Does the Surgical Approach Have an Impact on the Long-term Results?
Barlow's Disease · Prolapse; Mitral
Primary: Cardiac Death — 3.9; 3.8 percentage of participants with event
Phase 2 N=251 Comparing the Effectiveness of Repairing Versus Replacing the Heart's Mitral Valve in People With Severe Chronic Ischemic Mitral Regurgitation
Mitral Valve Insufficiency · Coronary Artery Disease
Primary: Degree of Left Ventricular Remodeling, as Assessed by Left Ventricular End Systolic Volume Index (LVESVI) — 54.6; 60.7 ml per square meter of body-surface area — p=0.18
N/A N=401 Evaluating the Benefit of Concurrent Tricuspid Valve Repair During Mitral Surgery
Mild Tricuspid Regurgitation · Moderate Tricuspid Regurgitation · Tricuspid Regurgitation
Primary: Percentage of Participants With Treatment Failure — 10.2; 3.9 percentage of participants
Phase 3 N=38 Molecular Mechanisms of Volume Overload-Aim 1(SCCOR in Cardiac Dysfunction and Disease)
Mitral Regurgitation
Primary: Left Ventricular End Diastolic Volume Indexed to Body Surface Area — 91.66; 95.74; 90.93; NA ml/m^2 — p=0.4568
N/A N=200 PRESERVE-MITRAL Post-Market Registry
Mitral Valve Disease
Primary: Improvement in Mitral Regurgitation (MR) Grade at 12-months Post Procedure — 97.8 percentage of participants
N/A N=301 Comparing the Effectiveness of a Mitral Valve Repair Procedure in Combination With Coronary Artery Bypass Grafting (CABG) Versus CABG Alone in People With Moderate Ischemic Mitral Regurgitation
Mitral Valve Insufficiency · Coronary Artery Disease
Primary: Degree of Left Ventricular Remodeling, as Assessed by Left Ventricular End Systolic Volume Index (LVESVI) — 49.6; 46.1 ml per square meter — p=0.61
N/A N=120 Carillon Mitral Contour System® for Reducing Functional Mitral Regurgitation
Mitral Valve Insufficiency · Heart Failure
Primary: Change in Baseline Regurgitant Volume Associated With the Carillon Device Relative to the Control Population at 12 Months — -7.07; 3.32 ml/beat
N/A N=19 NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study
Functional Mitral Regurgitation
Primary: The Primary Endpoint is Technical Success — 17 Participants
N/A N=81 COMPASSION - COngenital Multicenter Trial of Pulmonic VAlve Regurgitation Studying the SAPIEN InterventIONal THV
Pulmonary Valve Insufficiency · Pulmonary Regurgitation · Dysfunctional RVOT Conduit
Primary: Freedom From Device or Procedure Related Death or Reintervention — 97.1 percentage of participants
N/A N=88 Behavior of Valve Leaflets Following Aortic Valve Implant
Aortic-valve Replacement
Primary: Reduction in Leaflet Motion — 12 Participants
N/A N=30 Pleth Variability Index (PVI) as a Measure of Volume Status During Transcatheter Mitral Valve Repair
Mitral Regurgitation
Primary: Delta PVI to Delta LAP Correlation During MitraClip Placement — 4.30; -26.14 percentage of baseline (pre-MitraClip) — p=0.066
N/A N=756 Clinical Investigation Of The Mitroflow Aortic Pericardial Heart Valve
Heart Valve Diseases
Primary: Incidence Rate of Adverse Events and Mortality for the Mitroflow Aortic Heart Valve Repair — 7.1; 1.27; 0.21; 0.56 Percent occurrence per patient-year
N/A N=39 Magna Mitral - 23mm
Mitral Heart Valve Disease
Primary: Percent of Early Adverse Events Divided — 8.3; 0.0; 0.0; 0.0 percentage of subjects
N/A N=90 Transcatheter Valve Implantation in Patients With Dysfunctional Left and Right Sided Heart Valves
Eisenmenger Syndrome
Primary: Number of Participants Who Developed Infective Endocarditis — 9 participants
N/A N=12 5-Year Follow-Up Safety and Performance Evaluation of the Medtentia Annuloplasty Ring in Adults
Mitral Regurgitation · Mitral Insufficiency
Primary: Safety: the Occurrence, Nature and Frequency of Significant Medical Events — 0 Events
N/A N=14 REmodeling the Left Ventricle With Atrial Modulated Pacing
Heart Failure
Primary: Number of Participants Who Remained on Study — 9; 4 participants
N/A N=329 Magna® Mitral Pericardial Bioprostheses Post-Approval Study Protocol
Coronary Artery Disease · Mitral Valve Regurgitation · Mitral Valve Incompetence
Primary: Subject's Rate of Objective Performance Criteria Per ISO 5840-2005 - Total Number of Late Adverse Events (by Category) Divided by Late Patient Years (Expressed as a…
N/A N=279 Pivotal Study of a Percutaneous Mitral Valve Repair System
Mitral Valve Insufficiency · Mitral Valve Regurgitation · Mitral Valve Incompetence
Primary: Number of Participants With Major Adverse Events (MAE) — 13; 45 Participants
N/A N=191 Expanded Clinical Study of the Tendyne Mitral Valve System
Mitral Valve Regurgitation
Primary: Safety Endpoint: Number of Participants With Composite of Device Success and Freedom From Device or Procedure Related Serious Adverse Events (SAEs) — 120 Participants
N/A N=22 Endothelial Function and Cardiac Output in RV Pacing
Bradycardia
Primary: Endothelial Function Assessed by Flow Mediated Vasodilatation — 1.96; 1.73 EndoPAT index (EnFI)
N/A N=98 TRILUMINATE Study With Abbott Transcatheter Clip Repair System in Patients With Moderate or Greater TR
Tricuspid Valve Insufficiency
Primary: Number of Participants With Echocardiographic Tricuspid Regurgitation Reduction at Least 1 Grade — 71 Participants
N/A N=60 Hemodynamic Comparison of Tissue Aortic Valves
Aortic Valve Stenosis
Primary: Aortic Valve Mean Gradient (mm Hg) at Peak Exercise — 11; 14; 11 mm Hg
N/A N=91 Mitral Implantation of TRAnscatheter vaLves
Mitral Valve Disease
Primary: Technical Success at Exit From the Cath Lab. — 23; 20; 30 Participants
N/A N=78 EVEREST II Pivotal Study High Risk Registry (HRR)
Mitral Valve Insufficiency · Mitral Valve Regurgitation · Mitral Valve Incompetence
Primary: Composite Functional and Structural Measures - Freedom From Death — 59 Participants
N/A N=61 Cardioband With Transfemoral Delivery System
Mitral Regurgitation
Primary: Number of Participants With Major Serious Adverse Events and Serious Adverse Device Effects — 2; 1; 2; 4 Participants
N/A N=280 EDWARDS INTUITY Elite Valve System
Aortic Valve Disease · Aortic Stenosis
Primary: Subject's Average Time Spent on Cardiopulmonary Cross Clamp — 49.9; 65.2; 51.9 minutes